Abstract 5983
Background
Immunotherapy represents a new standard of care in first and second line treatment of advanced NSCLC. Immune related adverse events (irAEs) have been proposed as an indicator of treatment efficacy.
Methods
Retrospective analysis of mNSCLC patients treated with anti-PD/anti-PDL1 with or without anti-CTLA4 therapy. Electronic patient records were reviewed; irAEs were identified and graded according to CTC AE v4.03 criteria. The association with survival was evaluated in uni- (UV) and multivariable (MV) Cox-regression models.
Results
64 pts were identified; 41 (64.1%) were adenocarcinomas and 27 (42.2%) received immunotherapy in first-line. 44 pts (68.8%) received antiPD1/PDL1 monotherapy, and 20 pts (31.2%) received antiPDL1 + antiCTLA4. 15 pts (25%) developed irAEs: gastrointestinal (17.6%), endocrine (11.8%), cutaneous (17.6%), other (33.3%). Treatment was interrupted in 8 (53.3%) and suspended in 5 (33.3%) pts. 7 (50%) pts received high dose corticosteroids. No toxic deaths occurred. iRAEs were not significantly increased in pts receiving combination therapy (30% vs 20%, p = 0.377). Median OS was 6.5 m (95%CI: 0.24-12.7). Pts experiencing irAEs had a significantly higher OS (HR: 0.2; 95%CI: 0.07-0.58; p = 0.003) in UV analysis, and was independent of other prognostic factors in MV analysis (Table).Table: 1391P MV Cox-regression survival model
| Factor | HR (95%CI) | p-value |
|---|---|---|
| irAE (yes vs no) | 0.18 (0.06 – 0.53) | 0.002 |
| Histology | 1.11 (0.99 – 1.24) | 0.061 |
| ECOG PS | 0.82 (0.42 – 1.59) | 0.551 |
| Treatment line (first line vs second or further) | 1.06 (0.52 – 2.18) | 0.868 |
| Treatment type (monotherapy vs combination) | 2.25 (1.02 – 4.99) | 0.045 |
Conclusions
The development of irAEs may identify pts with a higher likelihood of benefitting from immunotherapy in NSCLC. These findings will require prospective validation in well-designed clinical trials.
Clinical trial identification
Legal entity responsible for the study
Instituto Investigación Sanitaria La Fe.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract